News Channels

06 Apr 2021 Molecular Templates to Prioritize Next-Generation ETB Candidates
06 Apr 2021 AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
06 Apr 2021 Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
06 Apr 2021 Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
06 Apr 2021 Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
06 Apr 2021 Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
06 Apr 2021 Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
06 Apr 2021 Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
06 Apr 2021 Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
05 Apr 2021 Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
05 Apr 2021 Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
02 Apr 2021 Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial
02 Apr 2021 Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
02 Apr 2021 Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
02 Apr 2021 OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
02 Apr 2021 US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
02 Apr 2021 AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
02 Apr 2021 CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
02 Apr 2021 Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
02 Apr 2021 Eloxx Pharmaceuticals Acquires Zikani Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up